Graves

Ibad Muhammad Muneeb; Mrinalini Srichandran; Sangeeth Veluchamy; Waseem Majeed; Natalie Gallant; Sarah Jamil; Rupinder Kochhar; Suhani Bahl; Lakdasa Premawardhana; Peter Taylor; Onyebuchi Okosieme; Colin Dayan; Adrian Heald

doi:10.1530/endoabs.117.P223

P223

Prev Next

Section Contents Cite

Endocrine Abstracts (2026) 117 P223 | DOI: 10.1530/endoabs.117.P223

SFEBES2026 Poster Presentations Thyroid (34 abstracts)

Graves’ disease: prospective 10 year outcomes for 100 consecutive individuals at a single centre

Muhammad Muneeb Ibad ¹ , Mrinalini Srichandran ¹ , Sangeeth Veluchamy ¹ , Waseem Majeed ¹ , Natalie Gallant ¹ , Sarah Jamil ¹ , Rupinder Kochhar ¹ , Suhani Bahl ² , Lakdasa Premawardhana ² , Peter Taylor ² , Onyebuchi Okosieme ² , Colin Dayan ² & Adrian Heald ³

Author affiliations

¹Salford Royal Hospital, Salford, United Kingdom; ²Cardiff University School of Medicine, Cardiff, United Kingdom; ³The School of Medicine and Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom

Introduction: The prevalence of Graves’ disease is approximately 1%. We undertook an evaluation of outcomes for 100 people diagnosed with Graves’ disease over a 10-year period.

Methods: All individuals were seen in the endocrinology outpatient clinic as consecutive presentations at a single UK centre. Individuals were first seen between 2012 and 2014. Individuals were first seen between 2012 and 2014.

Results: Of the 100 consecutive patients, 15 were male and 85 were female. The median age at diagnosis was 39.5 years(Interquartile Range(IQR):31-52) with median 43 years (IQR:31-61) for males and 39 years (IQR:31-51) for females. Eighty-seven individuals received carbimazole in the first year. 8 people were started on propylthiouracil, 3 did not receive any medical treatment while 2 received both propylthiouracil and carbimazole. Distribution of FT4 at baseline was skewed: median FT4 29.3pmol/l falling to 10-year median 16.2 pmol/l (Gaussian distribution). TSH was suppressed at baseline. TSH levels increased up to 5-year(1.10 mU/l); 10-year follow-up(1.15 mU/l). Over time, 25% continued to exhibit low/suppressed TSH levels, while 9% had elevated TSH levels. Overall, 37% individuals relapsed, 24% post-radioactive-iodine. For those who relapsed the median age at diagnosis was 34years (IQR:30-53) vs no relapse at 42years (IQR:32-52). At last/10-year follow-up 39% were euthyroid and not on therapy 22% remained on pharmacotherapy alone, 12% had undergone thyroid surgery, radioactive iodine alone 13% with combination treatment for 7%. 7% had died. Thyroid eye disease affected 26.7%males and 24.7%females. Baseline TRAb showed positive correlation with baseline FT4(Spearman’s rho=0.284, P = 0.004), with no significant association between baseline TRAb and relapse likelihood

Conclusion: Only about one third of patients remained in remission off anti-thyroid treatment, with a further one third requiring definitive treatment with thyroidectomy or radioactive iodine, demonstrating the potential for immunomodulatory therapy deployment in the future.